Commercial Credit Report for Eucrates Biomedical Acquisition Corp.

CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals. Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue. We also offer solutions that can help ease private company financial risk assessment. Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively.

A partial report preview for Eucrates Biomedical Acquisition Corp. is shown below. Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database. To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

	Eucrates Biomedical Acquisition Corp.
250 West 55th Street
Suite 13D
Phone: (212) 710-5220p:212 710-5220	New York, NY 10019 United States

This company ceased filing statements with the SEC on 5/8/2023.
On 4/11/2023, the Company announced it would not consummate a business combination and intends to dissolve and liquidate in accordance with the provisions of its Amended and Restated Memorandum and Articles of Association.
This company is no longer actively traded on any major stock exchange.

Business Summary

Eucrates Biomedical Acquisition Corp. is a blank check company. The Company is formed for the purpose of acquiring, engaging in a share exchange, share reconstruction and amalgamation with, purchasing all or substantially all of the assets of, entering into contractual arrangements with, or engaging in any other similar business combination with one or more businesses or entities. The Company intends to focus on businesses focusing on the biomedical or healthcare-related industries. The Company is not engaged in any business operations and has generated any revenue.

(Source: 10-K)

Scores and Ratings

FRISK^® Score	Z'' Score	PAYCE^® Score	DBT Index	Moody's Rating	Fitch Rating	DBRS Rating
-	Yes	-	-	-	-	-

Financials, News and Filings

Latest Statement	Last Audit	News	SEC Filings	Bankruptcy Filings	Suit & Judgment Filings	Tax Lien Filings
12/31/2022	12/31/2022	Yes	Yes	-	-	-

Industries

SIC Code	Description
6726	Unit investment trusts, face-amount certificate offices
6770	Blank checks

Officers and Directors

Title	Name	Age
Chairman of the Board	SteliosPapadopoulos	72
President, Chief Operating Officer, Director	EvangelosVergetis	42
Chief Executive Officer, Director	ParagSaxena	65
7 additional Officers and Directors records available in full report.

Business Names

Business Name
EUCR
EUCRU

General Information

Outstanding Shares:	4,206,059	(As of 4/13/2023)
Shareholders:	2
Stock Exchange:	NASD